Welcome to our dedicated page for Flora Growth SEC filings (Ticker: FLGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Flora Growth Corp. (NASDAQ: FLGC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it transitions toward a rebrand as ZeroStack and emphasizes its role as a decentralized AI treasury company and global pharmaceutical distributor. These filings, drawn from the SEC’s EDGAR system, document Flora’s corporate actions, financing arrangements and governance decisions in detail.
Investors can review Form 8-K current reports describing material events such as the 1-for-39 share consolidation, the company’s regaining of compliance with Nasdaq’s minimum bid price requirement, and multiple private placement transactions involving common shares, pre-funded warrants, common share purchase warrants and convertible notes. Specific 8-K filings outline cash and token-based private placements, a convertible note with DeFi Development Corp., a convertible note arrangement with Zero Gravity Labs Inc., and the company’s plans to use proceeds and tokens to further its digital asset treasury strategy linked to $0G.
The page also includes proxy materials such as the DEF 14A definitive proxy statement for the 2025 Special Meeting of Shareholders. That document details proposals for the name change to ZeroStack Corp., the creation of a new class of preferred shares, amendments to the 2022 Incentive Compensation Plan, approvals for option grants, approvals related to private placement issuances, authority for a forward share split, and potential adjournments. Additional filings describe amendments to the 2022 Incentive Compensation Plan and the repricing and vesting changes for certain stock appreciation rights.
Through Stock Titan, these SEC filings are updated in real time from EDGAR and are paired with AI-powered summaries that highlight key terms, capital structure changes, and treasury strategy disclosures. Users can quickly understand how Flora structures its digital asset-related financings, how it manages its Nasdaq listing requirements, and how shareholder approvals shape its evolution into ZeroStack. Forms such as 10-K and 10-Q, when available, complement the 8-K and proxy materials by providing broader financial and operational context.
ZeroStack Corp. director Laurence Zeifman reported a compensation-related award of options to buy 28,000 Common Shares. These director stock options have an exercise price of $5.10 per share and were granted at no cost.
The options vest in three equal installments: one-third on May 5, 2026, one-third on August 30, 2026, and one-third on December 31, 2026. Following this award, Zeifman holds 28,000 director stock options directly, with an expiration date of May 4, 2036.
ZeroStack Corp. director Edward Woo reported a compensation-related stock option grant on Common Shares. He received a Director Stock Option covering 35,000 shares, with an exercise price of $5.10 per share and an expiration date of May 4, 2036. Following this grant, he holds derivative rights over 35,000 shares directly. The options vest in three equal installments: one-third on May 5, 2026, one-third on August 30, 2026, and one-third on December 31, 2026. This Form 4 reflects an award acquisition rather than an open-market purchase or sale.
ZeroStack Corp. director Manfred Leventhal received a grant of 35,000 stock options. These Director Stock Options give him the right to buy 35,000 common shares at an exercise price of $5.10 per share and expire on May 4, 2036.
The options vest in three equal installments: one-third on May 5, 2026, one-third on August 30, 2026, and one-third on December 31, 2026. After this grant, he holds 35,000 options directly, reflecting a compensation award rather than an open-market trade.
ZeroStack Corp. reported that its independent directors approved new performance-based stock option grants for three senior leaders. The company granted 500,000 options to CEO Daniel Reis-Faria, 250,000 to CFO Dany Vaiman, and 500,000 to Executive Chairman Michael Heinrich.
The options have a $5.10 exercise price, a 10-year term, and are unexercisable until seven days after closing the Share Exchange Agreement involving Texas Blocker Corp. They are also subject to forfeiture unless shareholders approve them at the annual and special meeting expected on or about July 13, 2026. Vesting occurs in five 20% tranches when the share price reaches VWAP thresholds from $7.65 up to $17.85 on any trading day.
ZeroStack Corp. reported a net loss of $36.7 million for the three months ended March 31, 2026, driven mainly by a $60.7 million loss from changes in the fair value of its digital assets, primarily 0G Tokens. Revenue rose modestly to $7.3 million, including $2.8 million of 0G staking rewards, while pharmaceutical distribution contributed $4.5 million. Total assets fell to $45.2 million from $130.2 million as digital asset values and restricted holdings declined, though the company settled the Zero Gravity Convertible Note and reduced total debt to $3.2 million. Management now relies on staking income and recent equity financings to support a going concern outlook, but notes significant risk from heavy concentration in 0G and volatile cryptocurrency markets.
Michael Heinrich filed an amended ownership report for ZeroStack Corp., showing beneficial ownership of 471,208 common shares, equal to 10.0% of the outstanding common shares. He holds sole voting and dispositive power over these shares.
A related entity, Zero Gravity Labs Inc., now reports ownership of 0 shares of ZeroStack. On March 31, 2026, ZeroStack entered into a Note Settlement Agreement with Zero Gravity Labs under which payment of 50,000,000 Tokens fully satisfied the principal and interest of a prior convertible promissory note, eliminating further obligations under that note.
ZeroStack Corp. Executive Chairman Heinrich Michael reported an "other" restructuring transaction involving a convertible promissory note held indirectly through Zero Gravity Labs Inc., a corporation he owns and controls. The note was tied to 4,902,220 common shares at a conversion price of $33.34 per share and had an expiration date in September 2035. A note settlement agreement provides that payment of 50,000,000 Tokens to Zero Gravity Labs Inc. fully satisfies the principal and interest, leaving no further obligations under the note and no remaining derivative holdings from this instrument.
ZeroStack Corp. entered into a series of agreements tied to its Zero Gravity (0G) token holdings and a planned share exchange. Texas Blocker Corp., formed by ZeroStack’s CEO and CFO, received 142,232,948 0G Tokens from investors in return for 9,104,614 Texas Blocker common shares, valued at US$0.7549 per Token and US$11.7931 per Blocker Share.
ZeroStack then signed a Share Exchange Agreement to issue 9,104,614 ZeroStack common shares and/or pre-funded warrants in exchange for all outstanding Texas Blocker shares, after required shareholder approvals. On closing, Texas Blocker will become a wholly owned subsidiary and ZeroStack expects to be treated as a U.S. domestic corporation for federal tax purposes under Section 7874(b).
Separately, ZeroStack agreed to settle a prior token-denominated convertible note by delivering 50,000,000 Tokens to Zero Gravity Labs Inc., fully satisfying principal and interest and providing mutual releases. The ZeroStack securities are being issued in an exempt, unregistered private offering framework.
ZeroStack Corp., formerly Flora Growth, files its annual report describing a major pivot from legacy hemp and cannabis into a combination of decentralized AI-focused digital asset treasury management and global pharmaceutical distribution through its German unit Phatebo.
The company is building a treasury concentrated in 0G Tokens and other cryptocurrencies, funded by multiple 2025 private placements that raised about $14.6M in cash plus significant token consideration, and by borrowing 50,000,000 0G Tokens under a convertible note with related party Zero Gravity Labs. It also issued and settled a Solana-denominated convertible note and entered a large token-funded pre-funded warrant deal.
ZeroStack sold its legacy hemp and cannabis subsidiaries in 2025 to extinguish promissory note obligations and now focuses on AI-linked digital assets and pharmaceutical wholesaling. Despite this repositioning, it remains early stage and deeply loss-making, with a $119.7M net loss in 2025 and an accumulated deficit of $277.8M. As of February 23, 2026, it had 2,430,808 common shares outstanding and a small workforce of 21 employees.
ZeroStack Corp., formerly Flora Growth Corp., has officially changed its corporate name and Nasdaq ticker. Effective January 29, 2026, the company’s name changed from “Flora Growth Corp.” to “ZeroStack Corp.” following previously approved Articles of Amendment under Ontario corporate law.
On the same date, the company’s common shares stopped trading on the Nasdaq Capital Market under the ticker symbol “FLGC” and began trading under the new symbol “ZSTK”. The common shares also received a new CUSIP number, 98956L101 (ISIN: CA98956L1013). Existing share certificates remain valid and do not need to be exchanged.